2 446

Cited 21 times in

Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial.

DC Field Value Language
dc.contributor.author정현철-
dc.date.accessioned2014-12-20T16:55:59Z-
dc.date.available2014-12-20T16:55:59Z-
dc.date.issued2011-
dc.identifier.issn1340-6868-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/93654-
dc.description.abstractBACKGROUND: The primary objective of this multicenter, open-label, randomized, parallel, phase II selection trial was to compare the objective tumor response to biweekly (every 2 weeks) gemcitabine/paclitaxel, gemcitabine/carboplatin, and gemcitabine/cisplatin as first-line treatment for metastatic breast cancer. PATIENTS AND METHODS: Eligible patients with stage IV disease who relapsed after anthracycline failure were randomly assigned in a 1:1:1 ratio to gemcitabine (2,500 mg/m2) plus paclitaxel 150 mg/m2 (n = 49); plus carboplatin, area under the curve = 2.5 mg/mL × min (n = 47); or plus cisplatin 50 mg/m2 (n = 51). Study therapy continued up until a maximum of 8 cycles and follow-up continued for 24 months. RESULTS: All patients were analyzed for efficacy and one patient was excluded from the safety analyses. The objective response was 26.5% [95% confidence interval (CI) 14.9-41.1] for gemcitabine/paclitaxel, 17.0% (95% CI 7.6-30.8) for gemcitabine/carboplatin, and 15.7% (95% CI 7.0-28.6) for gemcitabine/cisplatin. The adjusted odds ratio for tumor response was 0.33 (95% CI 0.10-1.06), P = 0.063 for gemcitabine/carboplatin versus gemcitabine/paclitaxel; 0.26 (95% CI 0.08-0.86), P = 0.027 for gemcitabine/cisplatin versus gemcitabine/paclitaxel; and 0.77 (95% CI 0.24-2.52), P = 0.671 for gemcitabine/cisplatin versus gemcitabine/carboplatin. There were no significant differences in overall survival or progression-free survival (P > 0.05). Grade 3 or 4 drug-related adverse events varied between groups and the majority of deaths (94.9%; 74/78) were related to disease progression. CONCLUSIONS: The gemcitabine-based treatments had comparable activity and tolerability. Similar survival characteristics and different toxicity profiles suggested that gemcitabine-platinum may be evaluated further in patients after anthracycline failure.-
dc.description.statementOfResponsibilityopen-
dc.format.extent203~212-
dc.relation.isPartOfBREAST CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAnthracyclines/administration & dosage-
dc.subject.MESHAnthracyclines/adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHBreast Neoplasms/drug therapy*-
dc.subject.MESHBreast Neoplasms/mortality-
dc.subject.MESHBreast Neoplasms/pathology*-
dc.subject.MESHCarboplatin/administration & dosage-
dc.subject.MESHCarboplatin/adverse effects-
dc.subject.MESHCarcinoma, Ductal, Breast/drug therapy*-
dc.subject.MESHCarcinoma, Ductal, Breast/pathology-
dc.subject.MESHCisplatin/administration & dosage-
dc.subject.MESHCisplatin/adverse effects-
dc.subject.MESHDeoxycytidine/administration & dosage-
dc.subject.MESHDeoxycytidine/adverse effects-
dc.subject.MESHDeoxycytidine/analogs & derivatives-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPaclitaxel/administration & dosage-
dc.subject.MESHPaclitaxel/adverse effects-
dc.subject.MESHTreatment Outcome-
dc.titleBiweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorBinghe Xu-
dc.contributor.googleauthorZefei Jiang-
dc.contributor.googleauthorSung-Bae Kim-
dc.contributor.googleauthorShiying Yu-
dc.contributor.googleauthorJifeng Feng-
dc.contributor.googleauthorArtur Malzyner-
dc.contributor.googleauthorAuro del Giglio-
dc.contributor.googleauthorHyun C. Chung-
dc.contributor.googleauthorLi Jun Shen-
dc.contributor.googleauthorDaniel Lee Kay Pen-
dc.identifier.doi10.1007/s12282-011-0260-y-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03773-
dc.relation.journalcodeJ00401-
dc.identifier.eissn1880-4233-
dc.identifier.pmid21465229-
dc.identifier.urlhttp://link.springer.com/article/10.1007%2Fs12282-011-0260-y-
dc.subject.keywordGemcitabine-
dc.subject.keywordPaclitaxel-
dc.subject.keywordCarboplatin-
dc.subject.keywordCisplatin-
dc.subject.keywordBreast cancer-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.rights.accessRightsnot free-
dc.citation.volume18-
dc.citation.number3-
dc.citation.startPage203-
dc.citation.endPage212-
dc.identifier.bibliographicCitationBREAST CANCER, Vol.18(3) : 203-212, 2011-
dc.identifier.rimsid28369-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.